New Indian price caps would raise another hurdle to Big Pharma
Here's another chapter for the growing treatise known as Emerging Markets Are Tougher Than We Thought, by Big Pharma. India's newly proposed price controls would put another damper on drugmakers,...
View ArticleNovartis swings for fences in battle over Gleevec patent in India
So begins the court hearing that major pharma outfits with blockbuster ambitions in India are watching. Novartis has initiated its argument for the patentability of its hit cancer drug Gleevec in India...
View ArticleNCPA Digest Finds Independent Community Pharmacists Cut Costs Through Generic...
SAN DIEGO, Oct.read more
View ArticleGlobal High Potency Active Pharmaceutical Ingredients (HPAPIs) Market is...
ALBANY, New York, October 31, 2012 /PRNewswire/ --read more
View ArticleFTC: Generic-fighting product tweaks violate antitrust laws
The Federal Trade Commission's campaign for generic drugs has taken a new twist. The agency, long an opponent of "pay for delay" patent settlements, is now taking up the banner against product tweaks...
View ArticleSupreme Court to review key generic drug case
Can generics makers be held accountable for design flaws in the drugs they copy? That's the essential question in a case the U.S. Supreme Court has decided to review involving a Takeda Pharmaceutical...
View ArticleTeva Receives A- Rating from Fitch Ratings with a Stable Outlook
Teva Receives A- Rating from Fitch Ratings with a Stable Outlookread more
View ArticleFewer generics approved in 2012 but still a banner year
Given all of the lousy earnings reports and patent cliff talk, one might have expected last year to be the biggest ever for getting new generic drugs into the U.S. market. One would be wrong.read more
View ArticleCipla shoots South Africa's Cipla Medpro a better offer
India's Cipla and its namesake in South Africa, Cipla Medpro, may share a moniker but they haven't seen eye-to-eye on what it will take to share ownership.read more
View ArticleGeneric drugmakers concerned over FDA turmoil
Generic drugmakers are feeling a little taken advantage of. They produce 80% of the drugs used in the U.S. Their products are saving federal health programs billions of dollars and they are now helping...
View ArticleApotex, Waxman take sides against pharma in Supreme Court generics cases
The Supreme Court is hopping with pharma news these days. As the top U.S. court prepares to hear arguments tomorrow in the big generics-liability case, some key lawmakers in the generics world are...
View ArticleGenerics dampen US drug spending; payers fear rising specialty costs
It's confirmed: Another study shows that U.S. drug spending dropped ever so slightly last year. The obvious culprit is generic drugs, with major blockbusters such as Pfizer's ($PFE) Lipitor and...
View ArticleJustices weigh arguments in generic-liability case
How is a generic drug's label different from the drug itself? That was one of the many questions posed yesterday as the generics-liability case had its Supreme Court airing.read more
View ArticleSouth Africa follows India's lead with proposed drug-patent reforms
South Africa plans to revamp its intellectual-property laws to make it more difficult for pharma companies to win protection for new versions of older drugs. The move comes soon after India's top court...
View ArticleUnhappy with price caps at home, Indian drugmakers eye more U.S. growth
It's no big secret that international drugmakers are miffed at India. Revoking a few drug patents and overriding others will do that. But India's own pharma companies have their own beef with...
View ArticleOlder drugs aren't just cheaper, they're better, study says
Generic drugs already have cost on their side when competing with pricey brands. But according to a new study in Health Affairs, older meds may actually be more effective, too.read more
View ArticleUse prescription meds properly, save $200 billion a year
The good news from IMS Institute for Healthcare Informatics: Using prescription medicines properly could save $200 billion in annual U.S. healthcare costs. More good news, at least for the pharma...
View ArticleHow to save money via adherence? Let us count the (possible) ways
Patients, pharmacy benefits managers and drugmakers alike are trying to figure out how to save money through further generics use and better prescription adherence.read more
View ArticleThank pharma's patent cliff for helping to depress health-spending growth
U.S. healthcare spending is on the rise. But for the fourth year in a row, in 2012, those increases were comparatively modest, a new report says. As to whether it's the Affordable Care Act or lingering...
View ArticleBig Pharma accused of hatching 'satanic plot' in South Africa
South Africa's Minister of Health, Aaron Motsoaledi, lashed out on Friday at a report that Big Pharma is funding a PR campaign aimed at opposing new patent provisions favoring generic drugs, calling it...
View Article
More Pages to Explore .....